Do protocol transplant biopsies improve kidney transplant outcomes?

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 6, 2012, Pages 580-586

  Chapman, Jeremy R ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

calcineurin inhibitor nephrotoxicity; kidney biopsy; subclinical rejection; surveillance

Indexed keywords

CREATININE;

ANTICOAGULANT THERAPY; BK VIRUS INFECTION; CREATININE BLOOD LEVEL; HUMAN; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY INFECTION; KIDNEY TRANSPLANTATION; PATIENT SAFETY; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RENAL GRAFT DYSFUNCTION; REVIEW;

BIOPSY; CLINICAL PROTOCOLS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84868210823     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835903f4     Document Type: Review

References (50)

1. Burdick JF, McGraw D, Bender W, et al. Renal allograft infiltrate in the absence of rejection. Transplant Proc 1984; 16:1580-1582.
2. Rush DN, Henry SF, Jeffery JR, et al. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 1994; 57:208-211.
3. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9:2129-2134.
4. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326-2333.
5. Kurtkoti J, Sakhuja V, Sud K, et al. The utility of 1-and 3-month protocol biopsies on renal allograft function: a randomized controlled study. Am J Transplant 2008; 8:317-323.
6. Legendre C, Thervet E, Skhiri H, et al. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 1998; 65:1506-1509.
7. Cosio FG,Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5:2464-2472.
8. Furness PN, Philpott CM, Chorbadjian MT, et al. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation 2003; 76:969-973.
9. Schwarz A, Gwinner W, Hiss M, et al. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 2005; 5:1992-1996.
10. Anglicheau D, Loupy A, Lefaucheur C, et al. A simple clinico- histopathological composite scoring system is highly predictive of graft outcomes in marginal donors. Am J Transplant 2008; 8:2325-2334.
11. Munivenkatappa RB, Schweitzer EJ, Papadimitriou JC, et al. The Maryland aggregate pathology index: a deceased donor kidney biopsy scoring system for predicting graft failure. Am J Transplant 2008; 8:2316-2324.
12. Jain S, Curwood V, White SA, et al. Sub-clinical acute rejection detected using protocol biopsies in patients with delayed graft function. Transpl Int 2000; 13 (Suppl 1):S52-S55.
13. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donorspecific antibodies (DSA). Am J Transplant 2011; 11:56-65.
14. Audard V, Kamar N, Sahali D, et al. Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transpl Int 2012; 25:e62-e66.
15. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6:1841-1847.
16. Shishido S, Asanuma H, Nakai H, et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14:1046-1052.
17. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007; 7:2538-2545.
18. Seikku P, Krogerus L, Jalanko H, et al. Better renal function with enhanced immunosuppression and protocol biopsies after kidney transplantation in children. Pediatr Transplant 2005; 9:754-762.
19. Buchmann TN, Wolff T, Bachmann A, et al. Repeat true surveillance biopsies in kidney transplantation. Transplantation 2012; 93:908-913.
20. Moreso F, Carrera M, Goma M, et al. Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation 2012; 93:41-46.
21. Nemeth D, Ovens J, Opelz G, et al. Does borderline kidney allograft rejection always require treatment? Transplantation 2010; 90:427-432.
22. Anil Kumar MS, Irfan Saeed M, Ranganna K, et al. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Transpl Immunol 2008; 20:32-42.
23. Roberts IS, Stratopoulos C, Zilvetti M, et al. Impact of immunosuppression on the incidence of early subclinical renal allograft rejection: implications for protocol biopsy policy. Transpl Int 2009; 22:831-836.
24. Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2010; 10:2066-2073.
25. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157-1167.
26. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3:1017-1023.
27. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009; 9:1826-1834.
28. Setoguchi K, Ishida H, Shimmura H, et al. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation. Am J Transplant 2008; 8:86-94.
29. Nankivell BJ, Wavamunno MD, Borrows RJ, et al. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant 2007; 7:366-376.
30. Seron D, Moreso F. Protocol biopsies and risk factors associated with chronic allograft nephropathy. Transplant Proc 2002; 34:331-332.
31. Nankivell BJ, Borrows RJ, Fung CL, et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78:242-249.
32. Mengel M, Gwinner W, Schwarz A, et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007; 7:356-365.
33. Snanoudj R, Royal V, Elie C, et al. Specificity of histological markers of longterm CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011; 11:2635-2646.
34. Naesens M, Lerut E, Damme BV, et al. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant 2007; 7:2114-2123.
35. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18:22-28.
36. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4:1776-1785.
37. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12:210-217.
38. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547-557.
39. Hirsch HH. Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant 2002; 2:25-30.
40. Sharif A, Alachkar N, Bagnasco S, et al. Incidence and outcomes of BK virus allograft nephropathy among ABO-and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol 2012; 7:1320-1327.
41. Buehrig CK, Lager DJ, Stegall MD, et al. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 2003; 64:665-673.
42. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11:896-906.
43. Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando) 2009; 23:34-46.
44. Wavamunno MD, O'Connell PJ, Vitalone M, et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant 2007; 7:2757-2768.
45. Kobayashi A, Takahashi T, Horita S, et al. Clinicopathological impacts of activated transcription factor c-Jun in peritubular capillary endothelial cells in chronic antibody mediated rejection after kidney transplantation. Clin Nephrol 2012; 77:32-39.
46. Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17:952-960.
47. Dabade TS, Grande JP, Norby SM, et al. Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study. Am J Transplant 2008; 8:1318-1322.
48. Farris AB, Adams CD, Brousaides N, et al. Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc Nephrol 2011; 22:176-186.
49. Ho J, Rush DN, Karpinski M, et al. Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical tubulitis. Transplantation 2011; 92:878-882.
50. Anglicheau D, Muthukumar T, Hummel A, et al. Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis. Transplantation 2012; 93:1136-1146.